CytomX Therapeutics (CTMX) Equity Average (2016 - 2025)
Historic Equity Average for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to $113.6 million.
- CytomX Therapeutics' Equity Average rose 51569.71% to $113.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.6 million, marking a year-over-year increase of 51569.71%. This contributed to the annual value of -$24.0 million for FY2024, which is 6403.62% up from last year.
- As of Q3 2025, CytomX Therapeutics' Equity Average stood at $113.6 million, which was up 51569.71% from $72.5 million recorded in Q2 2025.
- CytomX Therapeutics' Equity Average's 5-year high stood at $113.6 million during Q3 2025, with a 5-year trough of -$86.2 million in Q1 2023.
- In the last 5 years, CytomX Therapeutics' Equity Average had a median value of -$27.3 million in 2024 and averaged -$12.9 million.
- In the last 5 years, CytomX Therapeutics' Equity Average plummeted by 65480.27% in 2022 and then surged by 51569.71% in 2025.
- CytomX Therapeutics' Equity Average (Quarter) stood at $15.0 million in 2021, then tumbled by 654.8% to -$83.1 million in 2022, then skyrocketed by 40.66% to -$49.3 million in 2023, then surged by 75.77% to -$12.0 million in 2024, then surged by 1050.72% to $113.6 million in 2025.
- Its Equity Average was $113.6 million in Q3 2025, compared to $72.5 million in Q2 2025 and $12.3 million in Q1 2025.